NCT06261294Completed
OncoSweep Cancer Spotlight and Spectrum Product Line
CONQUER Cancer Study: To Collect Blood Samples From Cancer and Non-cancer Participants for Development and Validation of the 'OncoSweep Cancer Spotlight and Spectrum Product Line
Source: ClinicalTrials.gov · Last updated 17 Sept 2025
Brief summary (registry, in English)
CONQUER cancer study: To collect blood samples from cancer and non-cancer participants for development and validation of the 'OncoSweep Cancer Spotlight and Spectrum Product Line'
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 109 (actual)
- First submitted
- 6 Feb 2024
- Start date
- 29 May 2023
- Primary completion date
- 3 Mar 2025
- Lead sponsor
- Pharus Taiwan, Inc.
- Diseases
- Lung cancer
- NCT number
- NCT06261294
What you commit to
- Study type: Observational
- Participants enrolled: 109
- From 29 May 2023 to the primary completion date, 3 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exclusion
- Individual who is not suitable for participating as per Investigator's judgement.
- Individual who has undergone gene therapy or related product within one year prior to enrolling in this study.
- Individual who is attending another clinical study at the time of enrollment.
- Individual who is known to be pregnant.
- Individual who has received a vaccine within two weeks.
- Individual who has a history of any cancer occurrences other than lung cancer.
Who the study is looking for
- Inclusion
- Individual who is not mentally impaired, capable to read, understand, and is willing to provide signed and dated informed consent form.
- Individual is aged 18 years old or above.
- Individual who is willing to provide information on the given questionnaire. Test group: Individual was diagnosed with pulmonary nodules or masses by low-dose CT (LDCT)/ CT, and evaluated by the physician needed to conduct a biopsy or/ and surgery has been arranged.
- Control group: Individual is willing to undergo LDCT or CT scan with 3-5 mm spatial z-axis resolution, pulmonary function examination, X-ray, laboratory blood test, and blood drawing.
- Control group: Individual has no abnormal finding from LDCT or CT scan with 3-5 mm spatial z-axis resolution and pulmonary function examination(FEV1/FVC Ratio≧70%).
- Individual did not donate blood or receive blood transfusion within two months before joining the study.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MacKay Memorial Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.